Relative effectiveness of high-dose versus standard-dose influenza vaccine against hospitalizations and mortality according to Charlson Comorbidity Index: A post-hoc analysis of the DANFLU-1 randomized trial

Read full text
Authors: Katrine Feldballe Bernholm, Niklas Dyrby Johansen, Caroline Espersen, Daniel Modin, Kira Janstrup Hyldekær, Joshua Nealon, Sandrine Samson, Matthew M. Loiacono, Rebecca C. Harris, Carsten Schade Larsen, Anne Marie Reimer Jensen, Nino Emanuel Landler
+11 more Signe Tellerup Nielsen, Lene Russel, Theis Skovsgaard Itenov, Brian L. Claggett, Scott D. Solomon, Martin J. Landray, Gunnar H. Gislason, Lars Køber, Pradeesh Sivapalan, Jens Ulrik Stæhr Jensen, Tor Biering-Sørensen
Cited by: 1
References: 30

Abstract

PURPOSE: The DANFLU-1 trial suggested lower incidence of hospitalizations for pneumonia and influenza, respiratory disease and all-cause mortality among older adults receiving high-dose (HD-IV) versus standard-dose (SD-IV) influenza vaccine. This study assessed the relative effectiveness of HD-IV versus SD-IV according to comorbidity in elderly individuals. METHODS: This was a post-hoc analysis of the DANFLU-1 randomized controlled feasibility trial of HD-IV versus SD-IV conducted during the 2021-2022 influenza season in adults aged 65-79 years. Outcomes assessed included influenza-related, respiratory, and cardiovascular hospitalizations, and mortality. We tested for effect modification by level of the Charlson Comorbidity Index (CCI) using ICD-10 codes up to 10 years prior to randomization. RESULTS: Of the 12,477 randomly assigned participants (mean age 71.7 ± 3.9 years, 47.1% female), 8,020 (64.3%) had CCI = 0, 3,560 (28.5%) had CCI = 1-2 and 893 (7.2%) had CCI ≥ 3. When comparing HD-IV with SD-IV, hazard ratios of hospitalizations for pneumonia and influenza were similar across CCI groups (HR [95%CI]: 0.15 [0.03-0.68] for CCI = 0, 0.36 [0.11-1.15] for CCI = 1-2, 1.00 [0.25-4.00] for CCI ≥ 3). Comparable patterns were found for hospitalizations for respiratory disease (0.46 [0.17-1.20] for CCI = 0, 0.67 [0.32-1.39] for CCI = 1-2, 0.66 [0.24-1.87] for CCI ≥ 3) and all-cause mortality (0.28 [0.09-0.86] for CCI = 0, 0.70 [0.30-1.63] for CCI = 1-2, 0.57 [0.24-1.36] for CCI ≥ 3). There was no statistical evidence of effect modification by CCI for any outcome. CONCLUSIONS: The lower incidences of clinical outcomes for HD-IV compared to SD-IV were not significantly modified by CCI. The potential benefit of HD-IV versus SD-IV may therefore be applicable regardless of comorbidity burden. Further research is required to confirm these findings.

Fields of Study & Subjects

Influenza Virus Research Studies Health Promotion and Cardiovascular Prevention Pneumonia and Respiratory Infections

Publication details

Journal / source
European Journal of Clinical Microbiology & Infectious Diseases
Publisher
Springer Science and Business Media LLC
Volume
45
Issue
5
Pages
1323–1332
Publication date
29 January 2026
Language
EN